Bli medlem
Bli medlem

Du är här

2016-05-18

Medigene AG: Medigene commissions EUFETS for cell production process for first own TCR studies

Medigene AG / Medigene commissions EUFETS for cell production process for
first own TCRstudies . Processed and transmitted by NASDAQ OMX Corporate
Solutions.The issuer is solely responsible for the content of this
announcement.
Martinsried/Munich, 18 May 2016.
Medigene AG(MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology
company focusing on the development of T-cell immunotherapies for the
treatment of cancer, has signed an agreement with the contract
manufacturerEUFETS GmbH, a subsidiary of BioNTech AG, for the production of
T-cell receptor-modified T cells. EUFETS will set up the cell production
together with Medigene for supplying the company's planned phase I/II TCR
studies.

In its own clinical TCR studies, Medigene plans to equip the patient's T cells
with specially selected T-cell receptors. This transduction called transfer
of genetic information is accomplished by viral vectors of the latest
generation that are also produced at EUFETS. As part of this new agreement,
the transduction and the subsequent cultivation and multiplication of T cells
will be carried out according to GMP1in the clean rooms at EUFETS. The
modified T cells are infused back into the patient's body where they should
identify and destroy the cancer cells.

Prof. Dolores Schendel, CEO and CSO of Medigene
, comments on the agreement: "As with the viral vectors, we want to secure the
necessary capacity for our first own TCR studies at an early stage. EUFETS is
very experienced in dealing with T cells and is therefore especially suited
as a partner. Since the necessary viral vectors are also produced by EUFETS,
administration and logistics are additionally simplified."

Dr. Klaus Kühlcke, Managing Director of EUFETS GmbH,
adds: "EUFETS will make an important contribution to the implementation of
these promising and exciting trials by producing both the vectors and the
genetically modified T cells. We are very pleased that this project will
further strengthen the good cooperation between EUFETS and Medigene."

About Medigene's TCR technology:
Medigene's technology for T-cell receptor-modified T cells is one of the
company's highly innovative and complementary immunotherapy platforms for
adoptive T-cell therapy. The TCR therapy is designed to treat patients with
high tumor loads. The clinical development of Medigene's TCRs is in
preparation.

The TCR technology aims at arming the patient's own T cells with
tumor-specific T-cell receptors. The receptor-modified T cells are then able
to detect and efficiently kill tumor cells. This immunotherapy approach
attempts to overcome the patient's tolerance towards cancer cells and
tumor-induced immunosuppression, by activating and modifying the patient's T
cells outside the body (ex-vivo
). A large army of specific T cells to fight the tumor is made available to
patients within a short period of time.

In the scope of this platform, Medigene is developing a comprehensive library
of recombinant T-cell receptors. Moreover, a good manufacturing practice
(GMP[1])-compliant process for their combination with patient-derived T cells
is currently being established.

Medigene is preparing the clinical development of its first product
candidates. In addition, novel TCRs with specificities for promising
tumor-associated antigens will be isolated and characterized. In the years
ahead, Medigene plans to initiate up to three clinical TCR trials, the first
to be started in 2016/2017 (IIT phase I study with participation of Medigene,
subject to grant funding). Medigene-sponsored trials are planned to start in
2017 and in 2018.

Further audio-visual education about Medigene's TCR technology
at:https://vimeo.com/123007480

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. The company is developing
highly innovative, complementary treatment platforms to target various types
and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized
T-cell-based immunotherapies.

For more information, please visitwww.medigene.com

About EUFETS

EUFETS GmbH, a subsidiary of BioNTech AG specializes in providing services in
the area of development and manufacture of cell-based and gene-based
therapeutics. EUFETS possesses comprehensive know-how in the development and
production of stem cell preparations, retroviral vectors, and genetic
modification of primary cells and cell lines. Since 1999, the company has
been GMP-certified, and is meanwhile recognized as a leading producer of
retroviral vectors for clinical trials worldwide. Since 2012, EUFETS has also
added the GMP manufacturing ofin vitro
transcribed mRNA to its portfolio.

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®is a registered trademark of Medigene
AG. This trademark may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor@medigene.com). We will then delete your address
from our distribution list.
---------------------------------------[1]Good Manufacturing Practice (GMP)are the practices required in order to
conform to the guidelines recommended by agencies that control authorization
and licensing for manufacture and sale of food, drug products, and active
pharmaceutical products.

Press release in English
http://hugin.info/132073/R/2013218/746167.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#2013218

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.